Abstract
AbstractAimsObservational research has identified links between micronutrient levels and chronic liver disease. However, the lack of randomized controlled experiments has impeded the ability to establish a cause‐and‐effect connection regarding micronutrients and cirrhosis of the liver. This Mendelian randomization (MR) analysis aimed to examine the causal impact of micronutrients on liver cirrhosis.MethodsWe selected genetic instrumental variables related to 12 micronutrients from genome‐wide studies on individuals of European descent, covering an array of over 9,851,867 single nucleotide polymorphisms and 460,351 participants. Data from patients with cirrhosis in the FinnGen database (https://www.finngen.fi/fi) were used. A two‐sample MR approach was employed to establish genetically causal estimates. Primary analyses used random effects and inverse variance weighted (IVW) methods, with additional sensitivity analyses for validation. MR–Egger intercept analysis and Cochran's Q test assessed horizontal pleiotropy and heterogeneity. Furthermore, multivariable Mendelian randomization (MVMR) was conducted to address potential confounding variables.ResultsIVW and weighted median methods showed that most micronutrients included were not significantly associated with a genetic susceptibility to liver cirrhosis. However, MR analysis demonstrated a significant association between circulating vitamin D levels and a reduced risk of liver cirrhosis (odds ratio IVW = 0.53, p < 0.010). The MR–Egger intercept showed no evidence of horizontal pleiotropy (p = 0.178), whereas Cochran's Q test found no heterogeneity (p = 0.799). Furthermore, MVMR analysis confirmed vitamin D was identified as a factor that independently mitigates the risk of liver cirrhosis.ConclusionThis research constitutes the most comprehensive MR investigation in this field, providing evidence supporting a protective link between circulating vitamin D levels and cirrhosis incidence. It suggests that maintaining sufficient vitamin D could be a cost‐effective strategy for early intervention in liver cirrhosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.